Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2026-01-25 Major Shareholding Noti…
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
股东拟减持股份的预披露公告
Major Shareholding Notification Classification · 95% confidence The document is a pre-disclosure announcement regarding a shareholder's plan to reduce their shareholding in the company. It details the shareholder's identity, the number and percentage of shares to be reduced, the method and period of reduction, and compliance with relevant laws and regulations. There is no financial performance data, earnings information, or management discussion. The document is a regulatory announcement about a shareholding change, specifically a planned reduction in shares by a significant shareholder. This fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, not a full report or announcement of a report publication.
2026-01-25 Chinese
第四届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 11th meeting of the 4th Board of Directors of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and references a related announcement about project delays. The content focuses on board meeting decisions and governance matters rather than financial results, audit, or shareholder voting outcomes. It is not a full annual or interim report, nor a call transcript or capital update. The document fits the category of Board/Management Information (MANG) as it announces board meeting resolutions and related governance information.
2025-12-22 Chinese
2025年第四次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions from the 2025 fourth extraordinary shareholders meeting of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the meeting date, attendance, voting results on a proposal to reappoint an audit firm, and legal opinions on the meeting's validity. The content is focused on shareholder meeting decisions and voting outcomes rather than the full annual or interim report, audit report, or other financial disclosures. It is not a full report but an official announcement of voting results from a shareholders meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (1323 characters), consistent with a voting results announcement rather than a full report.
2025-12-22 Chinese
关于北京三元基因药业股份有限公司2025年第四次临时股东会之法律意见书
Regulatory Filings Classification · 75% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, and voting results of an extraordinary shareholders’ meeting. It provides legal attestations rather than presenting financial data, investor materials, or simply announcing the vote tally alone. There is no direct category for a legal opinion on corporate actions, so it falls under the general Regulatory Filings fallback (RNS), which covers compliance documents and miscellaneous filings that don’t neatly fit other specific categories.
2025-12-22 Chinese
部分募投项目延期及重新论证公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Beijing Sanyuan Gene Pharmaceutical Co., Ltd. regarding the delay and re-evaluation of certain fundraising investment projects. It details the use of funds raised from a public offering of shares, the progress and delays in clinical trials, and the company's decisions to extend the expected completion dates of these projects. The document includes specific dates, project descriptions, regulatory references (e.g., NMPA guidelines), and mentions board and independent director meetings approving the delay. It is focused on the management and use of capital raised through equity issuance and the status of these capital projects. There is no detailed financial statement or comprehensive financial performance data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a simple announcement of a report publication but a substantive update on capital use and project progress. Therefore, the document fits best under Capital/Financing Update (CAP), as it provides detailed information on fundraising, capital usage, and project delays affecting capital deployment.
2025-12-22 Chinese
申万宏源证券承销保荐有限责任公司关于北京三元基因药业股份有限公司部分募集资金投资项目延期事项的核查意见
Regulatory Filings Classification · 85% confidence The document is a detailed sponsor’s due-diligence opinion on delay of IPO‐raised funds investment projects by Beijing Sanyuan Gene Pharmaceutical Co., Ltd., filed by the underwriting sponsor in compliance with Beijing Stock Exchange listing rules. It is not an annual or interim financial report, not a dividend or management change notice, nor a proxy or M&A filing. It is a compliance/regulatory disclosure and thus fits under the fallback category “Regulatory Filings (RNS).”
2025-12-22 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.